Alembic Pharmaceuticals has appointed Chirag Shukla as Company Secretary and Compliance Officer effective August 20, 2026. The firm disclosed the change in management to stock exchanges on the same date.

Shukla joins as a Key Managerial Personnel with permanent employment status. The appointment follows the company's compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. G Krishnan, Chief Financial Officer, signed the intimation letter submitted to the BSE and NSE.

Profile and Experience

Shukla is a qualified Company Secretary and Law Graduate with over 19 years of experience in corporate secretarial, legal, and compliance functions. His professional background includes roles at Deepak Phenolics Limited, a subsidiary of Deepak Nitrite Limited.

He has previously worked with Schaeffler India Limited, Alembic Limited, and Bhavnagar Energy Company Limited. His expertise covers compliance under the Companies Act, 2013, SEBI Regulations, corporate governance matters, and corporate restructuring.

Regulatory Disclosure

The company filed the details under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirmed no relationships between directors regarding this appointment.

Alembic Pharmaceuticals has revised its full-year revenue growth guidance for FY27 upward to the mid-teen range, up from the previously indicated low double-digit range. Managing Director Pranav Amin cited strong execution in the US generics segment, where growth is now expected to be in the mid-to-high teens, as the primary driver for this upgrade. This positive outlook follows a strong Q1FY27 performance, where consolidated revenue grew 26% year-on-year to ₹2,149.77 crore, driven by a 49% surge in US formulation sales.

Revised Growth Trajectory

During the post-results conference call held on August 4, 2026, management highlighted that the improved outlook is supported by volume-led growth rather than pricing power, amidst a competitive global environment. Amin stated that the US generics business, which delivered 49% growth in Q1FY27, is on track to sustain momentum due to a pipeline of 15+ product launches expected in the remainder of FY27. The company received 10 ANDA approvals during the quarter, bringing its total approved portfolio to 244 ANDAs, including 20 tentative approvals.

While the overall company growth guidance has been raised, management maintained that this does not signal a change in investment strategy. Alembic continues to allocate capital towards R&D, manufacturing debottlenecking, and the nascent US branded specialty platform. CFO G. Krishnan emphasized that the company remains disciplined on capital allocation while investing in long-term growth drivers such as peptide development and complex generic platforms.

Margin Dynamics and US Branded Business

A key focus of the earnings call was the impact of the new US branded specialty business on profitability. Management disclosed that Q1FY27 was the first full quarter of investment in this segment, resulting in a temporary drag on margins. Krishnan guided that the US branded business would cause an estimated 150 basis points of dilution in consolidated EBITDA margins for FY27.

However, he noted that the core business is demonstrating operating leverage, with underlying margins improving to the high teens. Amin projected that the branded business, currently in a "soft launch" phase with products like Pivya, will begin contributing positively to profits from FY28 onwards. He described the cost structure as primarily marketing and field force expenses, with no hardware or manufacturing investments required, expecting a J-curve trajectory where sales scale up after initial investment quarters.

Operational Highlights and Balance Sheet

In the domestic market, the India Branded Business grew 7% to ₹642 crore. While human health formulations faced headwinds, the Animal Health division delivered robust 24% growth, accounting for approximately 22% of India’s total revenue. Management appointed Ramesh Juneja as Sales and Marketing Head for Human Health to drive grassroots execution and improve productivity in underperforming territories. Amin indicated that positive trends in human health should emerge within the next two quarters.

The API segment grew 33% to ₹346 crore, benefiting from volume-led demand despite market pressures. For the full year, management expects API growth to remain around the 10% mark. Ex-US formulation revenues rose 17% to ₹383 crore, with management guiding for approximately 15% growth in INR terms for the full year.

On the balance sheet, gross debt stood at approximately ₹1,600 crore as of June 30, 2026, slightly higher than March levels due to increased receivables from higher sales volumes. Krishnan assured investors that this working capital build-up is temporary and should unwind in subsequent quarters, allowing debt levels to moderate back to March levels or lower. The company aims to maintain net debt close to 1x EBITDA.